Synchron Submits IPO Prospectus for Stentrode, a Neurovascular Stent-Electrode Hybrid Enabling Paralyzed Patients to Operate Digital Devices

U.S. Brain-Computer Interface CompanySynchronStentrode neurovascular stent, which received approval in August last yearFDA Breakthrough Device Designation。

The Stentrode implantation system consists ofCerebrovascular Stent, Implantable Transmission Unit, and External Terminalcomposition. In this system, the cerebrovascular stent is integrated with electrodes and implanted into the cerebral veins via minimally invasive endovascular surgery. The electrodes acquire neural signals from the brain, thereby serving as a brain-computer interface. Dedicated toTranslate the intention to attempt specific actions into wireless Bluetooth commands, thereby facilitating communication between patients and caregivers and improving their daily functional capabilities.The goal of this system isEnabling Paralyzed Patients to Use Digital Devices。

This June, Synchron, Inc.Series B Funding of $40 Million, and it has also secured funding support from the Australian government. This total funding of $59 million will be used to launch pivotal clinical studies in the United States to support FDA approval.

Synchron, Inc. is a spin-out company incubated by the University of Melbourne in Australia and has already initiated a clinical trial in Australia, enrolling4 Paralyzed PatientsThe system has been implanted, and their ability to control digital devices via thought is currently being evaluated to enhance functional independence.